Walleye Capital’s Insight Molecular Diagnostics IMDX Stock Holding History

Walleye Capital’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-518	Closed	-$14K	–	1060
2020 Q3	$14K	Buy	+518	New	+$14.9K	﹤0.01%	799

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital's IMDX Position: Q4 2020 in Review

Walleye Capital sold out of Insight Molecular Diagnostics (IMDX) in Q4 2020, closing a stake of 518 shares — an estimated $14K sold.

Walleye Capital first reported a position in IMDX in Q3 2020 and held it in 1 quarter. The position peaked at $14K in Q3 2020. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

Walleye Capital reported no remaining Insight Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
Walleye Capital sold 518 Insight Molecular Diagnostics shares in Q4 2020, an estimated $14K.
Walleye Capital first reported a position in Insight Molecular Diagnostics in Q3 2020 and held it in 1 quarter.
Walleye Capital's Insight Molecular Diagnostics position peaked at $14K in Q3 2020.
60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on Walleye Capital's 13F filing for Q4 2020, filed 16 Feb 2021.